RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.54
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$36.93

19 Dec
2024

-0.950

OPEN

$37.00

-2.51%

HIGH

$37.04

1,925,417

LOW

$36.66

TARGET
$40.12 8.6% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 143.7 xxx
DPS (cps) 32.5 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 25.6 xxx
Dividend Yield 0.9% xxx
Div Pay Ratio(%) 22.6% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.87%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.83

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/11 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx106.0
DPS All xxxxxxxxxxxxxxx29.6
Sales/Revenue xxxxxxxxxxxxxxx7,150.0 M
Book Value Per Share xxxxxxxxxxxxxxx495.8
Net Operating Cash Flow xxxxxxxxxxxxxxx2,138.4 M
Net Profit Margin xxxxxxxxxxxxxxx21.79 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx23.10 %
Return on Invested Capital xxxxxxxxxxxxxxx18.26 %
Return on Assets xxxxxxxxxxxxxxx15.25 %
Return on Equity xxxxxxxxxxxxxxx23.10 %
Return on Total Capital xxxxxxxxxxxxxxx24.60 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,555.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx53 M
Long Term Debt xxxxxxxxxxxxxxx1,256 M
Total Debt xxxxxxxxxxxxxxx1,309 M
Goodwill - Gross xxxxxxxxxxxxxxx4,256 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx357 M
Price To Book Value xxxxxxxxxxxxxxx5.87

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx175.3 M
Capex % of Sales xxxxxxxxxxxxxxx2.45 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,169 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,869 M
Research & Development xxxxxxxxxxxxxxx469 M
Investments - Total xxxxxxxxxxxxxxx227 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

28/10/2024

2

Accumulate

$40.05

8.45%

ResMed's 1Q revenues were 3% ahead of the consensus estimate due to higher rates of flow generator growth in the US and Rest of World, observes Ord Minnett.

Revenue growth of 11% resulted in 35% EPS growth, but the gross margin of 59.2% was in line with expectations, while expenses for SG&A and R&D were misses against the analyst's forecasts.

Target rises to $40.05 from $39.25. Accumulate.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

08/08/2024

2

Overweight

$33.83

-8.39%

An acceleration in year-on-year US mask growth to 17.4% from 12.1% in Q3 was a key highlight for Jarden from ResMed's 4Q result. This growth was partly due to another 62bps step-up in the gross margin to 59.1%, explain the analysts.

Management issued new FY25 guidance for a FY25 gross margin of between 59-60%.

The Overweight rating is maintained, and the target increased to $33.83 from $32.85.

FORECAST
Jarden forecasts a full year FY25 dividend of 37.04 cents and EPS of 147.69 cents.
Jarden forecasts a full year FY26 dividend of 46.24 cents and EPS of 164.47 cents.
Access Extra Coverage Research History >

RMD STOCK CHART

FNArena News on RMD

1
Rudi’s View: Banks, WiseTech, Redox & Integral Diagnostics

Dec 19 2024 - Rudi's View
2
Rudi’s View: Best Buys & Smaller Cap Favourites

Dec 12 2024 - Rudi's View
3
Rudi’s View: In Santa We Trust (?)

Dec 05 2024 - Rudi's View
4
Rudi’s View: A Cautious Preview Into 2025

Dec 04 2024 - Rudi's View
5
Rudi’s View: Trump Beneficiaries & TechOne

Nov 28 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
2
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
3
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
4
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
5
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
6
ResMed Silences The Doubters

Apr 29 2024 - Australia
7
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
8
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
9
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
10
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View